Generic competition · all medicines · read 12 November 2026
Is there a generic of Metoclopramide Hydrochloride, and who makes it?
Metoclopramide Hydrochloride appears in 6 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 11 generic makers listed as marketed across them. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came between 3.9 and 9.2 years after the first brand approval. This is the Orange Book's listing, not a forecast.
Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.
- Metoclopramide Hydrochloride appears in 6 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 11 generic makers listed as marketed across them.
- 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
- Where both are dated, the first generic approval came between 3.9 and 9.2 years after the first brand approval.
- Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.
Tablet, Oral
Four or more generic makers listed
Brand listed as marketed: Reglan. 4 generic makers with 8 generic products listed as marketed; the first generic approval is dated 29 July 1985.
| Generic maker (applicant) | First approval | Products |
|---|---|---|
| Teva Pharmaceuticals Usa Inc | 29 July 1985 | 2 |
| Aiping Pharmaceutical Inc | 30 January 1990 | 2 |
| Strides Pharma International Ag | 28 August 2006 | 2 |
| Ipca Laboratories Ltd | 12 June 2008 | 2 |
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
Injectable, Injection
Four or more generic makers listed
Every brand product here is listed as discontinued. 5 generic makers with 5 generic products listed as marketed; the first generic approval is dated 24 January 1986.
| Generic maker (applicant) | First approval | Products |
|---|---|---|
| Hospira Inc | 17 January 1991 | 1 |
| Teva Pharmaceuticals Usa | 27 November 1991 | 1 |
| Fresenius Kabi Usa Llc | 19 April 2013 | 1 |
| Avet Lifesciences Ltd | 20 December 2013 | 1 |
| Baxter Healthcare Corp | 11 September 2026 | 1 |
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
Solution, Oral
One to three generic makers listed
Every brand product here is listed as discontinued. 2 generic makers with 2 generic products listed as marketed; the first generic approval is dated 6 March 1987.
| Generic maker (applicant) | First approval | Products |
|---|---|---|
| Pai Holdings Llc Dba Pharmaceutical Associates Inc And Dba Pai Pharma | 28 May 1991 | 1 |
| Ani Pharmaceuticals Inc | 25 June 1993 | 1 |
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
Tablet, Orally Disintegrating, Oral
One to three generic makers listed
Every brand product here is listed as discontinued. 1 generic maker with 2 generic products listed as marketed; the first generic approval is dated 15 August 2014.
| Generic maker (applicant) | First approval | Products |
|---|---|---|
| Novel Laboratories Inc | 15 August 2014 | 2 |
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
Concentrate, Oral
Nothing listed as marketed
No brand application is listed. No generic is listed as marketed (1 generic product listed as discontinued).
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
Spray, Metered, Nasal
Brand listed, no generic listed as marketed
Brand listed as marketed: Gimoti. No generic is listed as marketed.
Patents and exclusivities still listed
- 22 December 2029Patent 11020361
- 22 December 2029Patent 12194009
- 22 December 2029Patent 12194008
- 22 December 2029Patent 11628150 drug product
- 22 December 2029Patent 11813231 drug product
- 16 May 2030Patent 8334281 drug product
- 17 November 2038Patent 12377064
US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.
Where can you go from this result?
Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.